Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 115.71 -1.22 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $116.93 | 52 Week High | $118.49 | |||
| Open | $116.75 | 52 Week Low | $55.00 | |||
| Day High | $116.87 | P/E | N/A | |||
| Day Low | $115.12 | EPS | $-0.56 | |||
| Volume | 1,476,823 | |||||
| (NASDAQ: MIRM) | Delayed: 80.39 -2.71 (3.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.10 | 52 Week High | $ | |||
| Open | $82.39 | 52 Week Low | $ | |||
| Day High | $83.00 | P/E | N/A | |||
| Day Low | $80.24 | EPS | $ | |||
| Volume | 788,216 | |||||
